Benzinga | May 5, 2021 09:26AM EDT

Northland Capital Markets Maintains Market Perform on Esperion Therapeutics, Lowers Price Target to $24

Northland Capital Markets analyst Carl Byrnes maintains Esperion Therapeutics (NASDAQ:ESPR) with a Market Perform and lowers the price target from $30 to $24.